Breaking News

OmniReliant Holdings Acquires Topical Pharmaceutical Patent

January 25, 2008

OmniReliant Holdings, Inc. of Tampa, FL has formally acquired the rights to a unique patented topical pharmaceutical product.

OmniReliant Holdings, Inc. of Tampa, FL has formally acquired the rights to a unique patented topical pharmaceutical product capable of delivering salicylic acid in a non-stick clear solid composition to treat acne. The company will use the patented product to compliment its patent pending warming foam acne treatment product.

According to the company, its lead scientists William Bess and Leonard Mackles, who conceived the product, have agreed to sell the patent and collaborate with OmniReliant Holdings, Inc. to bring the formula to the highly competitive acne treatment market.


  • Patent Activity: Colgate-Palmolive

    Patent Activity: Colgate-Palmolive

    December 6, 2016
    New oral care compositions, the use of radish root ferment filtrate in a cleanser and more.

  • Sparkle & Shine

    Sparkle & Shine

    Melissa Meisel, Associate Editor||November 21, 2016
    Glam packaging and upscale scent combos are big at Yankee Candle for Holiday 2016.

  • Cos Bar: Turning 40 and Hitting Fast Forward

    Cos Bar: Turning 40 and Hitting Fast Forward

    Christine Esposito, Associate Editor||November 21, 2016
    With a recent investor infusion, a new CEO and rebranding effort underway, this luxury beauty retailer has big plans.

  • Slow & Steady

    Slow & Steady

    Tom Branna, Editorial Director||December 1, 2016
    In a tumultuous environment, steady gains posted in the industrial and institutional cleaning sector are welcomed.

  • The World Comes to Orlando

    The World Comes to Orlando

    Tom Branna, Editorial Director||December 1, 2016
    More than 1,600 chemists traveled to Florida for the IFSCC Congress

  • The Plex  Phenomenon

    The Plex Phenomenon

    Denise Costrini, Croda North America||December 1, 2016
    Croda details the hair-protecting qualities of bond multipliers and the company’s new bond-building formulation system.